Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer

2011 ◽  
Vol 11 (6) ◽  
pp. 949-957 ◽  
Author(s):  
William M Hilton ◽  
Barbara Ercole ◽  
Dipen J Parekh ◽  
Guru Sonpavde ◽  
Rita Ghosh ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Intravesical Immunotherapy

scholarly journals Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer

2016 ◽  
Vol 6 (1) ◽  
pp. e1265720 ◽  
Author(s):  
Sonia Domingos-Pereira ◽  
Valérie Cesson ◽  
Mathieu F. Chevalier ◽  
Laurent Derré ◽  
Patrice Jichlinski ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Vaccine Strain ◽  
Invasive Bladder Cancer ◽  
Efficacy And Safety ◽  
Muscle Invasive Bladder Cancer ◽  
Preclinical Efficacy ◽  
Muscle Invasive ◽  
Intravesical Immunotherapy

scholarly journals Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer

2006 ◽  
Vol 6 ◽  
pp. 2611-2616 ◽  
Author(s):  
A.P.M. van der Meijden
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Chemotherapeutic Agent ◽  
Initial Therapy ◽  
Invasive Bladder Cancer ◽  
Bladder Tumors ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Intravesical Instillations ◽  
Intravesical Immunotherapy

According to clinical and pathological factors the prognosis of a patient with non-muscle invasive bladder tumors can be assessed. The prognosis is determined by the likelihood of recurrence(30-70%) and/or progression to muscle invasive bladder cancer(1-15%).Trans urethral resection of bladder tumors remains the initial therapy but adjuvant intravesical instillations are necessary.All patients benefit from a single immediate post operative instillation with a chemotherapeutic agent and for low risk tumors this is the optimal therapy.Patients with intermediate and high risk tumors need more intravesical chemo-or immunotherapy. Chemotherapy reduces recurrences but not progression. Intravesical immunotherapy(BCG) prevents or delays progression. Patients at high risk for progression may need upfront cystectomy.

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer

Urology ◽  
2020 ◽  
Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Racial Disparities ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

339: Selective Bladder Preservation by Transurethral Layer-Section in T2 Muscle-Invasive Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 114-115
Author(s):  
Young Deuk Choi ◽  
Kang Su Cho ◽  
Soung Yong Cho ◽  
Hyun Min Choi ◽  
Nam Hoon Cho
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document